Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5973543 | 0.84 | ALDH1A1 (0.61) | ALDH1A1GAAMAPK1MAPTPKM | |
| SCHEMBL28272959 | 0.84 | ALDH1A1 (0.56) | ALDH1A1GAAMAPK1NPC1RAB9A | |
| SCHEMBL14127136 | 0.84 | ALDH1A1 (0.56) | ALDH1A1GAAMAPK1RAB9AMAPT | |
| SCHEMBL11834129 | 0.81 | MEN1 (0.51) | ALDH1A1GAAMAPK1NPC1RAB9A | |
| SCHEMBL7218454 | 0.80 | SMN1; SMN2 (0.56) | ALDH1A1GAAMAPK1NPC1RAB9A | |
| SCHEMBL11371897 | 0.80 | GAA (0.44) | ALDH1A1GAAMAPK1NPC1RAB9A | |
| Ammonia Solution, Strong SCHEMBL28528068 | 0.80 | MEN1 (0.50) | ALDH1A1GAAMAPK1NPC1RAB9A | |
| SCHEMBL6630437 | 0.80 | LMNA (0.56) | ALDH1A1GAAMAPK1NPC1RAB9A | |
| SCHEMBL4744526 | 0.80 | MAPK1 (0.44) | ALDH1A1GAAMAPK1NPC1RAB9A | |
| SCHEMBL28015724 | 0.80 | GAA (0.44) | ALDH1A1GAAMAPK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341365-A1 | COMPOUNDS AS DNA PROBES, METHODS AND APPLICATIONS THEREOF | Jawaharlal Nehru Centre For Advanced Scientific Research (IN) | 2018-07-04 | — | — | EP | claimed |
| WO-2017033162-A1 | COMPOUNDS AS DNA PROBES, METHODS AND APPLICATIONS THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2017-03-02 | — | — | WO | claimed |
| CN-115504942-A | Synthesis method of alkyl or acyl substituted benzothiazole derivative | 汕头大学 | 2022-12-23 | — | — | CN | disclosed |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL MYERS SQUIBB CO (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8268871-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| US-8097615-B2 | Neurofibrillary labels | WISTA LABORATORIES LTD. (SG) | 2012-01-17 | — | — | US | disclosed |
| US-7943622-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100285605-A1 | Neurofibrillary labels | WISTA LABORATORIES LTD. | 2010-11-11 | — | — | US | disclosed |
| US-7795282-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | ALDH1A1 1082/4885GAA 446/4885MAPK1 1647/4885 |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | ALDH1A1 1082/4885GAA 446/4885MAPK1 1647/4885 |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | ALDH1A1 1082/4885GAA 446/4885MAPK1 1647/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | ALDH1A1 1082/4885GAA 446/4885MAPK1 1647/4885 |
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CHRNA7, CHRNA5, CHRNA2 | ALDH1A1 1032/4885GAA 1092/4885MAPK1 3555/4885 |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | ALDH1A1 1082/4885GAA 446/4885MAPK1 1647/4885 |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF2C, KIFC1 | ALDH1A1 2827/4885GAA 426/4885MAPK1 1486/4885 |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | CHRNA7, CHRNA5, CHRNA2 | ALDH1A1 1032/4885GAA 1092/4885MAPK1 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.